What it is
Cardiogen is a peptide bioregulator aimed at the heart and the blood vessels.
Bioregulators are very short chains of amino acids — shorter than most of the peptides on this site. That small size is the point of them. Less of a molecule means less for the immune system to react against, so the chance of an unwanted immune response is lower.
What separates a bioregulator from an ordinary peptide is where it acts. A signalling peptide works from outside the cell and its effect stops when the peptide is gone. A bioregulator is matched to one particular tissue, gets inside the cells of that tissue, binds to DNA, and changes which genes are switched on there. Since the genes concerned are the ones governing repair, regeneration, and ageing, the effects are thought to be deeper and last longer than a signalling peptide's.
Cardiogen's tissue is the heart. It is described as restoring normal protein production in cardiomyocytes — the muscle cells that make the heart contract — and as regulating the genes involved in cardiovascular health. The aim is to rebuild the natural signalling environment inside those cells, which in turn supports heart function and makes heart muscle more resilient.
It comes as a dry powder in a 20 milligram vial, mixed with bacteriostatic water — sterile water with a preservative so the mixed liquid keeps — and injected just under the skin.
Cardiogen is a peptide bioregulator with tropism for the myocardium and vascular system, described as restoring normal protein synthesis in cardiomyocytes and regulating gene expression associated with cardiovascular health, by way of re-establishing the intracellular signalling environment.
The class account: bioregulators are shorter-chain than conventional peptides, with correspondingly lower immunogenic potential; each is tissue-specific; each binds DNA and regulates gene expression within that tissue rather than acting as an extracellular signalling ligand. The claimed corollary is persistence — genes governing repair, regeneration, and longevity are activated or suppressed, so the effect is framed as outlasting the administration period, unlike signalling peptides whose action is confined to exposure.
No gene targets or binding data have been identified.
What is distinctive about Cardiogen relative to the other bioregulators on this site is that it has a full set of documented adverse effects, interactions, and contraindications — including an interaction list that is substantive and clinically relevant. That matters for a compound aimed at a population likely to be on cardiovascular pharmacotherapy already.
Presentation: 20 mg lyophilised vial, reconstituted with bacteriostatic water, subcutaneous administration at bedtime on 10–20 day courses.
What it does
The overall aim is a heart that holds up better under stress, ageing, and disease.
On protection: it guards the heart against damage, and makes heart tissue more able to withstand low oxygen, blocked blood supply, and oxidative stress — the wear caused by reactive molecules building up. It limits the damage done when blood flow or oxygen is cut off for a sustained period, which is what happens in a heart attack. It also reduces the impact of inflammation on heart tissue.
On rhythm and function: it normalises heart rhythm and the force of contractions, and helps regulate the electrical activity that drives the heartbeat.
On repair: it stimulates repair in damaged heart muscle, supports the regeneration of heart muscle cells and of the lining of blood vessels, and encourages the growth of capillaries — the smallest blood vessels — improving the blood supply reaching heart tissue.
On outcomes: it is described as reducing the number of strokes and heart attacks, and shortening recovery time after a heart attack. It offers support in irregular heart rhythm, high blood pressure, coronary heart disease, and diseases of the heart muscle.
On everyday capacity: it improves exercise tolerance and endurance, increases the heart's tolerance of both physical and emotional stress, and improves energy production in heart muscle so the heart tires less under strain.
It is recommended particularly for people with a family history of heart disease, and for athletes under heavy training loads.
Cardioprotection is the organising claim: enhanced myocardial resistance to hypoxia, ischaemia, and oxidative stress, with limitation of ischaemic damage and reduction of oxidative and inflammatory burden on cardiac tissue.
Electrophysiology and mechanics: normalisation of heart rhythm and contractile force, with regulation of cardiac electrophysiological activity.
Regeneration and perfusion: stimulation of repair in damaged myocardium; support for cardiomyocyte and vascular endothelial regeneration; enhanced capillary growth and blood supply to cardiac tissue; improved endothelial and microcirculatory function.
Clinical outcomes named: reduced incidence of stroke and myocardial infarction; reduced post-infarction recovery time; adjunct support in arrhythmias, hypertension, coronary heart disease, and cardiomyopathy. Also named as a research and clinical adjunct in ischaemic heart disease and myocarditis, and in recovery after cardiac surgery or prolonged illness.
Functional capacity: improved exercise tolerance and endurance; increased myocardial tolerance of physical and emotional stress; improved myocardial energy metabolism with reduced cardiac fatigue under strain.
Metabolic: stated potential in metabolic syndrome, assisting with cardiac complications tied to diabetes, hypertension, and obesity.
Longevity framing: cardiovascular longevity through optimised gene regulation and protein synthesis, consistent with the class mechanism.
Target populations named explicitly are family history of heart disease and athletes under high training strain — note the second sits directly alongside a stated adverse effect of cardiac overstimulation in sensitive individuals.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- Protects the heart, and makes heart tissue better able to withstand low oxygen, blocked blood supply, and oxidative stress.Anecdotal
- Normalises heart rhythm and the strength of contractions, and helps regulate the heart's electrical activity.Anecdotal
- Limits the damage caused when blood flow or oxygen to the heart is cut off for a sustained period.Anecdotal
- Reduces the impact of oxidative stress and inflammation on heart tissue.Anecdotal
- Stimulates repair in damaged heart muscle, and supports regeneration of heart muscle cells and of the lining of blood vessels.Anecdotal
- Encourages the growth of capillaries, improving blood supply to heart tissue.Anecdotal
- Supports blood supply to the heart muscle, improving how well the heart performs.Anecdotal
- Reduces the number of strokes and heart attacks, and shortens recovery time after a heart attack.Anecdotal
- Provides support in irregular heart rhythm, high blood pressure, coronary heart disease, and disease of the heart muscle.Anecdotal
- Improves exercise tolerance and endurance.Anecdotal
- Increases the heart's tolerance of physical and emotional stress.Anecdotal
- Improves energy production in heart muscle, so the heart tires less under strain.Anecdotal
- May enhance recovery after heart surgery or a long illness.Anecdotal
- May help with heart-related complications of diabetes, high blood pressure, and obesity.Anecdotal
- Improves the function of the lining of blood vessels and of the smallest circulation.Anecdotal
- Supports long-term heart health by influencing gene regulation and protein production.Animal or lab only
- Recommended particularly for those with a family history of heart disease, and for athletes under heavy training loads.Anecdotal
- Myocardial protection: enhanced resistance of cardiac tissue to hypoxia, ischaemia, and oxidative stress.Anecdotal
- Improved circulation: supports blood supply to the heart muscle, enhancing cardiac performance.Anecdotal
- Normalisation of heart rhythm: regulates cardiac electrophysiological activity and contractile force.Anecdotal
- Limits ischaemic damage; reduces the impact of oxidative stress and inflammation on cardiac tissue.Anecdotal
- Post-infarction recovery: promotes repair and regeneration after myocardial injury; reduces recovery time.Anecdotal
- Supports cardiomyocyte and endothelial regeneration; enhances capillary growth and cardiac tissue perfusion.Anecdotal
- Reduces incidence of stroke and myocardial infarction.Anecdotal
- Adjunct in cardiovascular disease: arrhythmias, hypertension, ischaemic heart disease, myocarditis, cardiomyopathies.Anecdotal
- Cardiovascular longevity: supports long-term cardiac health by optimising gene regulation and protein synthesis.Animal or lab only
- Stress resistance: increases myocardial tolerance of physical and emotional stress.Anecdotal
- Anti-fatigue: improves myocardial energy metabolism, reducing cardiac fatigue under strain.Anecdotal
- Improves exercise tolerance and endurance.Anecdotal
- Support during rehabilitation: may enhance recovery after cardiac surgery or prolonged illness.Anecdotal
- Potential in metabolic syndrome: assists with cardiac complications tied to diabetes, hypertension, and obesity.Anecdotal
- Vascular modulation: improves endothelial and microcirculatory function.Anecdotal
- Named target populations: family history of heart disease; athletes under high training strain.Anecdotal
Reconstitution and dosing
The vial holds 20 milligrams (mg). Mix it with 2 millilitres (mL) of bacteriostatic water. On an insulin syringe that is the 200 mark, because 100 units is 1 mL. Add the water slowly down the inside wall of the vial rather than onto the powder, then swirl gently. Do not shake.
With 20 mg in 2 mL, every unit on the syringe holds 100 micrograms. So 2 milligrams is 20 units.
Inject under the skin, once a day, at bedtime.
A cycle runs 10 or 20 days — both are used — and there is only one dose, 2 milligrams, held flat for the whole course. There is no ramp up or down.
Guidance on how often to repeat it is inconsistent. One recommendation is 2 or 3 cycles per year; another is to repeat 3 to 4 times per year. The two do not agree, and there is no clear way to choose between them. The more conservative reading is 2 to 3 cycles.
The difference between a 10-day and a 20-day cycle is not explained either. There is no stated reason to pick one over the other.
Presentation: 20 mg vial reconstituted with 2 mL (200 units) of bacteriostatic water, giving 10 mg/mL — 100 mcg per insulin unit. Add diluent down the vial wall and swirl; do not shake.
Recomputed draw: 2 mg = 20 units. Exact; the single dose level carries no discrepancy.
Administration: subcutaneous, once daily at bedtime. No rationale given for the nocturnal timing, and no postprandial constraint is stated.
Cycle: 10 or 20 days, flat dosing at 2 mg throughout — no titration in either direction, unusual against the graded schedules elsewhere on this site and unexplained. The choice between the 10-day and 20-day courses is left open with no criterion.
Inconsistent guidance on cycle frequency. One dosing recommendation gives 2 or 3 cycles per year; another gives repetition 3 to 4 times per year. These are inconsistent and no resolution is available. The protocol below carries the conservative reading, 2–3 cycles annually, and flags the discrepancy; the higher figure would roughly double annual exposure at the 20-day course length.
Total exposure: 20 mg per 10-day course, 40 mg per 20-day course — one or two vials respectively.
20 mg vial
Mix with 2 mL (200 units) of BAC water, giving 10 mg/mL — 100 mcg per insulin unit.
10 mg/mL · 100 mcg per unit
Cycle: 10-day or 20-day cycle. Guidance varies between 2–3 cycles per year and 3–4 times per year; the conservative reading is used here · Frequency: 1×/day at bedtime; subcutaneous
| When | Dose | Draw | How often |
|---|---|---|---|
| Every day of the 10- or 20-day cycle (2 mg) | 2 mg | 20 units | 1×/day |
20 mg in 2 mL is 10 mg/mL, or 100 mcg per unit. Draw 20 units (0.2 mL) for 2000 mcg.
Who should avoid it
- Anyone with a known allergy or sensitivity to peptide preparations.
- Anyone with severe **decompensated cardiac failure** — heart failure that has stopped being controlled and is causing active symptoms — unless under medical supervision.
- Anyone pregnant or breastfeeding.
- Anyone under 18. It is not for use in children.
- Be careful with heart medicines. Cardiogen may interact with cardiovascular drugs, and may complement treatments for irregular heart rhythm, heart muscle disease, or blocked coronary arteries — so the combined effect should be monitored. Complementing a drug is not automatically good: if a medicine and Cardiogen push in the same direction, the total effect can overshoot.
- Be careful with antioxidant treatments. Cardiogen reduces oxidative stress, and so do they, so the benefits may add together in a way that needs watching.
- Be careful when combining with other bioregulators that act on metabolism. Pancragen and Endoluten are named specifically. The combination may increase the overall effect on the body and therefore needs the doses balanced.
- Talk to a doctor before starting, and go through your full medication list with them.
- Known allergy or hypersensitivity to peptide preparations.
- Severe decompensated cardiac failure without medical supervision.
- Pregnancy and lactation: contraindicated.
- Paediatric use: not indicated.
- Cardiovascular pharmacotherapy: stated potential interaction. It is framed as complementary to therapy for arrhythmias, cardiomyopathies, and ischaemic heart disease, with monitoring required for synergistic effects — read that as an additive-effect caution rather than an endorsement, particularly with rate- or rhythm-controlling agents given the stated electrophysiological action.
- Antioxidant therapies: caution on additive benefit through shared reduction of oxidative stress.
- Other metabolic bioregulators: Pancragen and Endoluten are named, with the note that combination may enhance systemic effect and therefore requires dose balancing.
- Worth reading alongside the adverse effect list: cardiac overstimulation in sensitive individuals is a stated adverse effect, which bears directly on the arrhythmia and athletic-population framing elsewhere in this entry.
Side effects
- Irritation where you inject — redness, swelling, or itching.
- Rare allergic reactions, in people who turn out to be sensitive to the peptide components.
- Possible overstimulation of the heart's activity in sensitive individuals. Note this sits alongside the claim that Cardiogen normalises heart rhythm — the same action, pushed too far in the wrong person.
- No guidance is available on what to monitor, or on what overstimulation would feel like. A racing, pounding, or irregular heartbeat is the obvious thing to take seriously.
- Injection site irritation: erythema, swelling, and/or pruritus.
- Rare allergic reactions arising from hypersensitivity to peptide components.
- Potential overstimulation of cardiac activity in sensitive individuals — the counterpart of the stated rhythm-normalising and electrophysiological action, and the adverse effect most consequential given the target population.
- No monitoring parameters, no description of what overstimulation presents as, and no discontinuation criterion. Palpitations, tachycardia, or new arrhythmia would be the events to act on.
User reports
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
Named as a caution rather than a recommendation. Combining Cardiogen with metabolic bioregulators like Pancragen may increase the overall effect on the body, and that the doses therefore need balancing. Its own page covers the pancreas and blood sugar.
Named in the interaction data, framed as requiring dose balancing on account of enhanced systemic effect rather than offered as a protocol. The overlap is plausible on the metabolic syndrome framing this page raises — cardiac complications of diabetes and obesity — but no combined schedule exists and the wording is cautionary.
- Endoluten
The other bioregulator named in the same caution. There is no page for it on this site. As with Pancragen, the point is that combining them may increase the total effect and so needs the doses balanced, not that it is recommended.
Named alongside Pancragen in the interaction section as a metabolic bioregulator whose combination may enhance systemic benefit and require dose balancing. No page exists for it on this site, and no further detail is available.
- Antioxidant therapies
Flagged as something to use caution with, not something to add. Cardiogen lowers oxidative stress and antioxidant treatments do the same, so the effects may add up more than intended.
Named in the interaction section as a caution on additive benefit through shared reduction of oxidative stress. Listed here because it is an obvious combination to reach for and caution is explicitly advised rather than encouragement.
Dosing figures have been reviewed and units are recomputed from the stated protocol.